M-protein analysis of streptococcus pyogenes isolates associated with acute rheumatic fever in New Zealand

Journal of Clinical Microbiology

Volumn 53, Issue 11, 2015, Pages 3618-3620

  Williamson, Deborah A ^a,b,c   Smeesters, Pierre R ^d,e   Steer, Andrew C ^d,e   Steemson, John D ^f   Ng, Adrian C H ^f   Proft, Thomas ^b   Fraser, John D ^b   Baker, Michael G ^c   Morgan, Julie ^a   Carter, Philip E ^a   Moreland, Nicole J ^b,f  

^a INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

M PROTEIN; STREPTOCOCCUS VACCINE; BACTERIAL ANTIGEN; CARRIER PROTEIN; OUTER MEMBRANE PROTEIN; STREPTOCOCCAL M PROTEIN;

ARTICLE; BACTERIAL GENE; BACTERIAL SKIN DISEASE; BACTERIUM ISOLATE; DISEASE ASSOCIATION; EMM GENE; GENE CLUSTER; GROUP A STREPTOCOCCAL INFECTION; HUMAN; MOLECULAR EPIDEMIOLOGY; NEW ZEALAND; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PYODERMA; RETROSPECTIVE STUDY; RHEUMATIC FEVER; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PYOGENES; VACCINE PRODUCTION; CLASSIFICATION; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MOLECULAR TYPING; PATHOGENICITY; PROCEDURES; STREPTOCOCCAL INFECTIONS;

ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; HUMANS; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; NEW ZEALAND; RETROSPECTIVE STUDIES; RHEUMATIC FEVER; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 84945208027     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02129-15     Document Type: Article

References (17)

1. Jaine R, Baker M, Venugopal K. 2008. Epidemiology of acute rheumatic fever in New Zealand 1996-2005. J Paediatr Child Health 44:564-571. http://dx.doi.org/10.1111/j.1440-1754.2008.01384.x.
2. Beall B, Facklam R, Thompson T. 1996. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol 34:953-958.
3. Stollerman GH. 1971. Rheumatogenic and nephritogenic streptococci. Circulation 43:915-921. http://dx.doi.org/10.1161/01.CIR.43.6.915.
4. Erdem G, Mizumoto C, Esaki D, Reddy V, Kurahara D, Yamaga K, Abe L, Johnson D, Yamamoto K, Kaplan EL. 2007. Group A streptococcal isolates temporally associated with acute rheumatic fever in Hawaii: differences from the continental United States. Clin Infect Dis 45:e20-e24. http://dx.doi.org/10.1086/519384.
5. Reissmann S, Gillen CM, Fulde M, Bergmann R, Nerlich A, Rajkumari R, Brahmadathan KN, Chhatwal GS, Nitsche-Schmitz DP. 2012. Region specific and worldwide distribution of collagen-binding M proteins with PARF motifs among human pathogenic streptococcal isolates. PLoS One 7:e30122. http://dx.doi.org/10.1371/journal.pone.0030122.
6. Dinkla K, Talay SR, Mörgelin M, Graham RM, Rohde M, Nitsche-Schmitz DP, Chhatwal GS. 2009. Crucial role of the CB3-region of collagen IVin PARF-induced acute rheumatic fever. PLoS One 4:e4666. http://dx.doi.org/10.1371/journal.pone.0004666.
7. Moreland NJ, Waddington CS, Williamson DA, Sriskandan S, Smeesters PR, Proft T, Steer AC, Walker MJ, Baker EN, Baker MG, Lennon D, Dunbar R, Carapetis J, Fraser JD. 2014. Working towards a group A streptococcal vaccine: report of a collaborative Trans-Tasman workshop. Vaccine 32:3713-3720. http://dx.doi.org/10.1016/j.vaccine.2014.05.017.
8. Dale JB, Penfound TA, Tamboura B, Sow SO, Nataro JP, Tapia M, Kotloff KL. 2013. Potential coverage of a multivalent M protein-based group A streptococcal vaccine. Vaccine 31:1576-1581. http://dx.doi.org/10.1016/j.vaccine.2013.01.019.
9. Sanderson-Smith M, De Oliveira DM, Guglielmini J, McMillan DJ, Vu T, Holien JK, Henningham A, Steer AC, Bessen DE, Dale JB, Curtis N, Beall BW, Walker MJ, Parker MW, Carapetis JR, Van Melderen L, Sriprakash KS, Smeesters PR, M Protein Study Group. 2014. A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development. J Infect Dis 210: 1325-1338. http://dx.doi.org/10.1093/infdis/jiu260.
10. Baroux N, D'Ortenzio E, Amedeo N, Baker C, Ali Alsuwayyid B, Dupont-Rouzeyrol M, O'Connor O, Steer A, Smeesters PR. 2014. The emm-cluster typing system for group A Streptococcus identifies epidemio-logic similarities across the Pacific region. Clin Infect Dis 59:e84-92. http://dx.doi.org/10.1093/cid/ciu490.
11. Atatoa-Carr P, Lennon D, Wilson N, New Zealand Rheumatic Fever Guidelines Writing Group. 2008. Rheumatic fever diagnosis, management, and secondary prevention: a New Zealand guideline. N Z Med J 121:59-69.
12. Williamson DA, Morgan J, Hope V, Fraser JD, Moreland NJ, Proft T, Mackereth G, Lennon D, Baker MG, Carter PE. 2015. Increasing incidence of invasive group A streptococcus disease in New Zealand, 2002-2012: a national population-based study. J Infect 70:127-134. http://dx.doi.org/10.1016/j.jinf.2014.09.001.
13. Williamson DA, Moreland NJ, Carter P, Upton A, Morgan J, Proft T, Lennon D, Baker MG, Dunbar R, Fraser JD. 2014. Molecular epidemiology of group A streptococcus from pharyngeal isolates in Auckland, New Zealand, 2013. N Z Med J 127:55-60.
14. Shulman ST, Tanz RR, Dale JB, Steer AC, Smeesters PR. 2014. Added value of the emm-cluster typing system to analyze group A Streptococcus epidemiologyin high-income settings. Clin Infect Dis 59:1651-1652. http://dx.doi.org/10.1093/cid/ciu649.
15. Parks T, Smeesters PR, Steer AC. 2012. Streptococcal skin infection and rheumatic heart disease. Curr Opin Infect Dis 25:145-153. http://dx.doi.org/10.1097/QCO.0b013e3283511d27.
16. New Zealand Ministry of Health. 2015. Rheumatic Fever. New Zealand Ministry of Health, Wellington, New Zealand. http://www.health.govt.nz/our-work/diseases-and-conditions/rheumatic-fever.
17. Dale JB, Penfound TA, Chiang EY, Walton WJ. 2011. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine 29:8175-8178. http://dx.doi.org/10.1016/j.vaccine.2011.09.005.